Stockscreener 앱 받기
0.4453
4.03%
-0.0187
전일 마감가:
$0.464
열려 있는:
$0.47
하루 거래량:
10,869
Relative Volume:
0.03
시가총액:
$10.35M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+17.18%
1개월 성능:
-10.00%
6개월 성능:
-45.70%
1년 성능:
-65.21%
1일 변동 폭
$0.4406
$0.478
1주일 범위
$0.3768
$0.478
52주 변동 폭
$0.3176
$2.58
Cellyan Biotechnology Co Ltd Stock (HKPD) Company Profile
Compare HKPD vs MCK, COR, CAH, HSIC, AHG
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HKPD
Cellyan Biotechnology Co Ltd
|
0.4406 | 10.33M | 0 | 0 | 0 | 0.00 |
MCK
Mckesson Corp
|
803.50 | 92.06B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
304.90 | 57.69B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
241.28 | 55.96B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
86.47 | 9.85B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.525 | 1.30B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cellyan Biotechnology Co Ltd 주식(HKPD)의 최신 뉴스
12 Industrials Stocks Moving In Tuesday's Pre-Market Session - Benzinga
[EFFECT] Cellyan Biotechnology Co., Ltd SEC Filing - Stock Titan
Cellyan Biotechnology (HKPD) Slides 3.78% to $0.40 as Biotech Volatility PersistsLong Term Entry Picks - dars.gov.et
Cellyan Biotech (HKPD) Slides 7.6%, Testing Key Support at $0.39Channel Projection - newsline.com
Cellyan Biotechnology (NASDAQ: HKPD) files $200M shelf to sell shares, debt - Stock Titan
Cellyan Biotechnology (HKPD) director CHAN Kam Leung files initial Form 3 - Stock Titan
12 Industrials Stocks Moving In Wednesday's After-Market Session - Benzinga
[Form 3] Cellyan Biotechnology Co., Ltd Initial Statement of Beneficial Ownership - Stock Titan
12 Industrials Stocks Moving In Tuesday's Intraday SessionBimergen Energy (AMEX:BESS), EHang Holdings - Benzinga
Cellyan Biotechnology (HKPD) Chief Strategy Officer listed with no Form 3 transactions - Stock Titan
Cellyan Biotechnology (HKPD) CFO Liu Shu files initial ownership Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) director Zhou Mike Yao files initial Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) director Wu Jingyan submits initial SEC Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) CEO and director files Form 3 with no share transactions - Stock Titan
Cellyan Biotechnology (HKPD) Slumps 7.83%: Key Support at $0.50 Under PressureFibonacci Fan - The Legal Advocate
Cellyan Biotechnology (HKPD) Holds Steady Near Support After Marginal GainsAdvance Decline Volume - The Legal Advocate
HKPDCellyan Biotechnology Co Ltd Stock Price and Quote - Finviz
Cellyan Biotechnology (HKPD) Drops 3.6% as Shares Approach Critical $0.50 SupportButterfly Setup - The Legal Advocate
Cellyan Biotechnology Faces Resistance at $0.57 After Recent DeclineTotal Put Call - newsline.com
12 Industrials Stocks Moving In Wednesday's Pre-Market SessionBrenmiller Energy (NASDAQ:BNRG), Smart P - Benzinga
Cellyan (HKPD) quarterly earnings report shows no revenue, EPS data available amid biotechnology sector headwinds.Shared Buy Zones - Newser
What net volume Cellyan (HKPD)? (Smart Money Outflows) 2026-04-29Buy Signals - newser.com
What leverage Cellyan (HKPD)? | HKPD Latest Quarter Earnings: Cellyan logs zero revenue, advances key drug pipeline progressSocial Trading Insights - newser.com
HKPD Latest Quarter Earnings: Cellyan logs zero revenue, advances key drug pipeline progressPretax Income Report - The Legal Advocate
12 Industrials Stocks Moving In Friday's Pre-Market Session - Benzinga
HKPD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HKPD (Cellyan) posts 21.7 percent Q2 2025 revenue growth, shares drop 6.58 percent amid negative earnings.Dividend Increase Stocks - The Legal Advocate
Cellyan (HKPD) Stock: Is It Ready for Entry (Institutional Demand) 2026-04-18Index Investing - Cổng thông tin điện tử tỉnh Lào Cai
HKPD Technical Analysis & ETF Price Forecast - Intellectia AI
HKPD Stock Analysis: Cellyan Biotechnology Co. Ltd gains 1.59% to trade at 0.57 dollar - newsline.com
12 Industrials Stocks Moving In Monday's Intraday Session - Benzinga
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), the selling shareholders of Cellyan Biotechnology Co Ltd may sell up to 12.5 million Class A ordinary shares from time to time in the future. - Bitget
12.5M shares for resale — Cellyan Biotechnology (NASDAQ: HKPD) - stocktitan.net
Cellyan Biotechnology (HKPD) completes $6.5M private unit financing - Stock Titan
If You Invested $1,000 in Cellyan Biotechnology Co Ltd (HKPD) - Stock Titan
Cellyan Biotechnology Reports Lower Revenue and Profit in Latest Interim Results - TipRanks
Cellyan Biotechnology (HKPD) interim revenue and profit drop sharply in 2025 - Stock Titan
Cellyan Biotechnology Co., Ltd Reports Earnings Results for the Half Year Ended September 30, 2025 - marketscreener.com
HKPD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
12 Industrials Stocks Moving In Tuesday's After-Market Session - Benzinga
PETS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cellyan Biotechnology receives Nasdaq bid price deficiency notice - MSN
Cellyan Biotechnology boosts share capital and completes name change after December AGM - MSN
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency - The Manila Times
Cellyan Biotechnology receives Nasdaq minimum bid price deficiency notice - Investing.com
Cellyan Biotechnology Hit With Nasdaq Bid-Price Deficiency Notice, Shares Remain Listed - TipRanks
12 Industrials Stocks Moving In Thursday's Pre-Market Session - Benzinga
Cellyan Biotechnology Co Ltd (NASDAQ:HKPD) - intelligentinvestor.com.au
Cellyan Biotechnology Co Ltd (NASDAQ: HKPD)Share Price - intelligentinvestor.com.au
Cellyan Biotechnology Boosts Share Capital and Completes Name Change After December AGM - TipRanks
Cellyan Biotechnology Co Ltd (HKPD) 재무 분석
Cellyan Biotechnology Co Ltd (HKPD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.34%
3.87%
자본화:
|
볼륨(24시간):